219 related articles for article (PubMed ID: 30723186)
1. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017.
Checchi M; Mesher D; Mohammed H; Soldan K
Sex Transm Infect; 2019 Aug; 95(5):368-373. PubMed ID: 30723186
[TBL] [Abstract][Full Text] [Related]
2. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis.
Canvin M; Sinka K; Hughes G; Mesher D
Sex Transm Infect; 2017 Mar; 93(2):125-128. PubMed ID: 27365492
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
5. Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women.
Brotons M; Monfil L; Roura E; Duarte-Salles T; Casabona J; Urbiztondo L; Cabezas C; Bosch FX; de Sanjosé S; Bruni L
Prev Med; 2020 Sep; 138():106166. PubMed ID: 32565118
[TBL] [Abstract][Full Text] [Related]
6. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
Vaccine; 2016 Sep; 34(39):4678-4683. PubMed ID: 27527815
[TBL] [Abstract][Full Text] [Related]
7. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study.
Sandø N; Kofoed K; Zachariae C; Fouchard J
Acta Derm Venereol; 2014 May; 94(3):288-92. PubMed ID: 24150529
[TBL] [Abstract][Full Text] [Related]
8. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination.
Naleway AL; Crane B; Smith N; Francisco M; Weinmann S; Markowitz LE
Sex Transm Dis; 2020 Mar; 47(3):179-186. PubMed ID: 31880738
[TBL] [Abstract][Full Text] [Related]
9. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada.
Steben M; Ouhoummane N; Rodier C; Sinyavskaya L; Brassard P
J Med Virol; 2018 Mar; 90(3):592-598. PubMed ID: 28980715
[TBL] [Abstract][Full Text] [Related]
10. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
12. Impacts of Human Papillomavirus Immunization Programs on Rates of Anogenital Warts in British Columbia, Canada, 2000 to 2017.
Lukac CD; Donken R; Otterstatter M; Mazo O; Wong S; Marra F; Smith L; Naus M; Money D; Krajden M; Grennan T; Gilbert M; Wong J; Ogilvie GS
Sex Transm Dis; 2020 Oct; 47(10):691-697. PubMed ID: 32649583
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
[TBL] [Abstract][Full Text] [Related]
14. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
15. Incidence of anogenital warts after the introduction of the quadrivalent HPV vaccine program in Manitoba, Canada.
Righolt CH; Willows K; Kliewer EV; Mahmud SM
PLoS One; 2022; 17(4):e0267646. PubMed ID: 35472093
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of human papillomavirus vaccination strategies among men who have sex with men in China: a modeling study.
Li Y; Lin YF; Wu X; Zhou X; Tian T; Guo Z; Fu L; Yang L; Lu Z; Fan S; Lu Y; Ke W; Zou H
Front Immunol; 2023; 14():1197191. PubMed ID: 37426648
[TBL] [Abstract][Full Text] [Related]
17. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18.
Chow EPF; Carter A; Vickers T; Fairley CK; McNulty A; Guy RJ; Regan DG; Grulich AE; Callander D; Khawar L; Machalek DA; Donovan B
Lancet Infect Dis; 2021 Dec; 21(12):1747-1756. PubMed ID: 34339639
[TBL] [Abstract][Full Text] [Related]
18. Health service utilisation for anogenital warts in Ontario, Canada prior to the human papillomavirus (HPV) vaccine programme introduction: a retrospective longitudinal population-based study.
Guerra FM; Rosella LC; Dunn S; Wilson SE; Chen C; Deeks SL
BMJ Open; 2016 Mar; 6(3):e009914. PubMed ID: 26966057
[TBL] [Abstract][Full Text] [Related]
19. Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.
Mann LM; Llata E; Flagg EW; Hong J; Asbel L; Carlos-Henderson J; Kerani RP; Kohn R; Pathela P; Schumacher C; Torrone EA
J Infect Dis; 2019 Apr; 219(9):1389-1397. PubMed ID: 30500908
[TBL] [Abstract][Full Text] [Related]
20. Partial Protective Effect of Bivalent Human Papillomavirus 16/18 Vaccination Against Anogenital Warts in a Large Cohort of Dutch Primary Care Patients.
Woestenberg PJ; Guevara Morel AE; Bogaards JA; Hooiveld M; Schurink-van 't Klooster TM; Hoebe CJPA; van der Sande MAB; van Benthem BHB
Clin Infect Dis; 2021 Jul; 73(2):291-297. PubMed ID: 32421775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
